Smoking Cessation
Conditions
Keywords
schizophrenia spectrum disorder
Brief summary
The purpose of this study is to assess the feasibility and safety of injectable naltrexone (NTX;380 mg) in conjunction with oral bupropion (BUP; 450 mg daily)NTX-BUP administration among individuals with schizophrenia spectrum disorders that smoke cigarettes and to evaluate change on smoking-related measures and symptoms of schizophrenia.
Interventions
DRUGNaltrexone (Vivitrol)
At week 1 the Nurse Practitioner will administer extended-release naltrexone via intramuscular gluteal injection supplied as a standard single-use kit containing 380-mg vial of Vivitrol microspheres. Only one naltrexone injection will be administered over the course of the study
DRUGBupropion
Oral bupropion will be titrated to 450 mg over the course of 3 days. One week's supply of the study medication will be dispensed at each visit. Cell-phone assisted remote observation of medication adherence (CAROMA) will be used to assess compliance. Following Week 3, participants will be provided with enough pills to titrate the dose of bupropion over a period of 4 days. Therefore, participants will receive bupropion pills 3 weeks plus 4 additional days to titrate down the dose.
Sponsors
The University of Texas Health Science Center, Houston
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* fluent in English; * Diagnosed with schizophrenia spectrum disorder that is currently stable; * Report regular cigarette smoking, average cigarette per day ≥ 5 in the past 4 weeks, and present a breath CO≥10 ppm. * Meet subjective and objective (urinary drug screen) measures of non-opioid use. * If female, present a negative pregnancy test, not be currently breast feeding, and agree to use acceptable birth control methods and receive periodic pregnancy tests during the course of the study. * Able to give written informed consent * Obtain an Evaluation to Sign Consent (ESC) score above 10.
Exclusion criteria
. * Have suicidal or homicidal ideation requiring immediate attention. * Previous use of bupropion or naltrexone in the past 30 days. * Currently enrolled in treatment for tobacco use. * Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5 )criteria for alcohol and other substance use disorders excluding nicotine and marijuana. * Report a history of epilepsy, seizure disorder or condition increasing risk of seizure, or head trauma with neurological sequelae. * Have a current eating disorder. * Be medically unstable or taking medications that are contraindicated with using naltrexone or bupropion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility as assessed by the percentage of participants that enroll in the study | end of treatment (week 3) |
| Percentage of participants that complete 3 weeks of treatment | end of treatment (week 3) |
| Safety as assessed by the percentage of participants that show no serious adverse events | end of treatment (week 3) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in number of cigarettes smoked per day (CPD) | Baseline, end of treatment (week 3) | — |
| Change in psychiatric symptoms as assessed by the score on the Brief Psychiatric Rating Scale (BPRS) | Baseline, end of treatment (week 3) | This is an 18 item questionnaire and each is scores from 1 (not present) to 7 (extremely severe),with a total score between 18 and 126, higher number indicating worse outcome |
| Change in smoking urges as assessed by the Questionnaire on Smoking Urges (QSU) | Baseline, end of treatment (week 3) | This is a 10 item questionnaire and each is cored from 0(strongly disagree) to 10(strongly agree) for a maximum score of 100, higher score indicating more smoking urge |
| Reduction in number of cigarettes consumed when price is at 0 as assessed by the Cigarette Purchasing Task (CPT) | Baseline, end of treatment (week 3) | This will utilize a hypothetical purchasing task, which will assess hypothetical purchase and consumption of cigarettes as a function of increasing cigarette price. |
Countries
United States
Outcome results
None listed